Summary:
Colossal Biosciences raised $120 million to support its mission of resurrecting extinct animals, with investors including Peter Jackson.
The startup aims to bring back the dodo bird within seven years, leveraging recent scientific advancements in avian cell growth.
This funding extends a previous $200 million round, boosting the company's valuation to $10.3 billion and highlighting strong investor confidence.
A key breakthrough involves growing pigeon cells in a lab, which could lead to new technologies for protecting endangered species and de-extinction efforts.
The progress positions Colossal at the forefront of biotechnology and conservation, potentially revolutionizing how we address species loss.
Colossal Biosciences Inc. Secures Major Funding for De-Extinction
Colossal Biosciences Inc., a pioneering biotechnology startup focused on resurrecting extinct animals, has successfully raised $120 million in a recent funding round. This investment includes backing from high-profile figures like filmmaker Peter Jackson, underscoring the growing interest and confidence in de-extinction technologies.
The CEO of Colossal has announced an ambitious timeline, expecting to bring back the dodo bird in less than seven years. This latest funding is an extension of a $200 million round disclosed earlier, catapulting the company's valuation to an impressive $10.3 billion.
In a significant scientific breakthrough, Colossal reported on Wednesday that they have grown pigeon cells in a laboratory setting. This advancement marks a pivotal moment in avian science, potentially enabling new methods to protect endangered birds and even revive extinct species like the dodo. The progress opens doors to innovative conservation efforts and could reshape our approach to biodiversity loss.
Comments